The cell and gene therapy platform developer hopes to accelerate cell therapy product development.
Ori Biotech, the London and Philadelphia-based developer of a platform that helps cell and gene therapy manufacturing, has launched a preferred partner network to accelerate the development and commercialisation of cell and gene therapies.
The founding members of the Ori Preferred Partner Network in the US include Charles River Laboratories, a joint venture between MD Anderson Cancer Center and Resilience called CTMC, ElevateBio, Kincell and a number of other currently undisclosed partners.
“By partnering with the top academic institutions and CDMOs globally, Ori is helping to deliver proven solutions that speed time to clinic, reduce comparability risk, and shorten development timelines,” said Ori Biotech chief executive Jason Foster.
For service providers, developing and manufacturing cell therapies, membership of the network have the opportunity to accelerate cell therapy product development via the new Ori Biotech platform.
This partnership approach, the company said, helps ensure that Ori and its partners remain at the cutting edge of cell therapy manufacturing innovation.
Preferred access
Network members will get preferred access to Ori innovations, including its IRO platform, which can increase throughput, reduce costs of goods and accelerate development timelines.
IRO was designed to integrate with other upstream and downstream technologies and provide a streamlined and closed workflow.
“Ori’s mission mirrors our own: expedite the delivery of life-saving therapies to patients,” said Matthew Hewitt, chief technology officer of the manufacturing business division at Charles River. “By joining Ori’s preferred partner network, we can support the advanced therapies industry by helping to drive the adoption of cutting-edge closed and automated platforms, and address manufacturing bottlenecks.”
Foster talked to Healthcare Today in February about the application of AI and machine learning in drug discovery. “The potential of AI is significant, with the possibility of accelerating drug development timelines by approximately three years, speeding up both clinical development and the transition to commercial-scale manufacturing,” he said.
